E
TVTX icon

Ergoteles’s Travere Therapeutics TVTX Stock Holding History

Ergoteles’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-53,899
Closed -$1.33M – 1898
2022
Q3 		$1.33M Buy
+53,899
New +$1.39M 0.05% 387
2022
Q1 		– Sell
-33,898
Closed -$1.05M – 1635
2021
Q4 		$1.05M Buy
+33,898
New +$955K 0.04% 406

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ergoteles's TVTX Position: Q4 2022 in Review

Ergoteles sold out of Travere Therapeutics (TVTX) in Q4 2022, closing a stake of 53,899 shares — an estimated $1.33M sold.

Ergoteles first reported a position in TVTX in Q4 2021 and held it in 2 quarters. The position peaked at $1.33M in Q3 2022. 155 funds tracked by Wall St. Rank hold TVTX as of Q4 2022.

  • Ergoteles reported no remaining Travere Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 53,899 Travere Therapeutics shares in Q4 2022, an estimated $1.33M.
  • Ergoteles first reported a position in Travere Therapeutics in Q4 2021 and held it in 2 quarters.
  • Ergoteles's Travere Therapeutics position peaked at $1.33M in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.